LLY vs NOTV
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
NOTV exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9, indicating severe fundamental weakness. The company is facing a liquidity crisis with a Current Ratio of 0.30 and a Quick Ratio of 0.17, suggesting it cannot meet its short-term obligations. High leverage (Debt/Equity of 4.37) combined with stagnant revenue growth (0.80%) and consistent earnings misses creates a high risk of insolvency. The catastrophic 5-year price decline of 98.8% and bearish insider activity further confirm a negative outlook.
Compare Another Pair
Related Comparisons
LLY vs NOTV: Head-to-Head Comparison
This page compares Eli Lilly and Company (LLY) and Inotiv, Inc. (NOTV) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.